Vanguard Group Inc Cardiff Oncology, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,171,444 shares of CRDF stock, worth $5.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,171,444
Previous 2,136,338
1.64%
Holding current value
$5.6 Million
Previous $4.74 Million
22.25%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CRDF
# of Institutions
90Shares Held
12.3MCall Options Held
813KPut Options Held
91.1K-
Black Rock Inc. New York, NY2.63MShares$6.78 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA928KShares$2.39 Million0.0% of portfolio
-
State Street Corp Boston, MA833KShares$2.15 Million0.0% of portfolio
-
Mai Capital Management663KShares$1.71 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny602KShares$1.55 Million0.0% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $112M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...